Related references
Note: Only part of the references are listed.Can the UK 'Netflix' Payment Model Boost the Antibacterial Pipeline?
Colm Leonard et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2023)
The antibiotic subscription model: fostering innovation or repackaging old drugs?
Rebecca E. Glover et al.
LANCET MICROBE (2023)
An Analysis of Antibacterial Drug Development Trends in the United States, 1980-2019
Nidhi Dheman et al.
CLINICAL INFECTIOUS DISEASES (2021)
Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines
Kevin Outterson
HEALTH AFFAIRS (2021)
Resetting the agenda for antibiotic resistance through a health systems perspective
Otto Cars et al.
Lancet Global Health (2021)
Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization
Kevin Outterson et al.
TRANSLATIONAL RESEARCH (2020)
Social, cultural and economic aspects of antimicrobial resistance
Timo Minssen et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2020)
Designing development programs for non-traditional antibacterial agents
John H. Rex et al.
NATURE COMMUNICATIONS (2019)
Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance
John H. Rex et al.
CLINICAL INFECTIOUS DISEASES (2017)
Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach
John H. Rex et al.
LANCET INFECTIOUS DISEASES (2016)
Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality
Kevin Outterson et al.
PLOS MEDICINE (2016)